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Abstract: Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular 
patterns (DAMPs) are recognized by different cellular pathogen recognition receptors (PRRs), which 
are expressed on cell membrane or in the cytoplasm of cells of the innate immune system. Nucleic 
acids derived from pathogens or from certain cellular conditions represent a large category of 
PAMPs/DAMPs that trigger production of type I interferons (IFN-I) in addition to pro-inflammatory 
cytokines, by specifically binding to intracellular Toll-like receptors or cytosolic receptors. These 
cytosolic receptors, which are not related to TLRs and we call them “Toll-free” receptors, include the 
RNA-sensing RIG-I like receptors (RLRs), the DNA-sensing HIN200 family, and cGAS, amongst 
others. Viruses have evolved myriad strategies to evoke both host cellular and viral factors to evade 
IFN-I-mediated innate immune responses, to facilitate their infection, replication, and establishment of 
latency. This review outlines these “Toll-free” innate immune pathways and recent updates on their 
regulation, with focus on cellular and viral factors with enzyme activities. 
Keywords: PRR; cGAS; IFN-I; innate immunity 
 
1. Introduction  
Pathogen-associated molecular patterns (PAMPs) are usually derived from invading pathogens, 
and initiate rigorous innate immune responses after recognized by host germline-encoded pathogen 
recognition receptors (PRRs), which are expressed on cell membrane or in the cytoplasm of cells in the 
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innate immune system. PRRs include the well-known transmembrane Toll-like receptors (TLRs), and 
an increasing pool of Toll-unrelated receptors (so we call them “Toll-free” receptors hereafter) that 
include retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), Caterpiller-like receptors (CLRs), 
the HIN200/PYHIN family of nuclear antigens, cGMP-AMP synthase (cGAS), DNA-dependent 
activator of IRFs (DAI) [1], DDX9, DDX36 [2], DDX41 [3,4], RNA polymerase III [5], Ku70 [6], 
MRE11 [7], Sox2 [8], LRRFIP1 [9], ISG56/IFIT1 [10] and OASs [11], amongst others [12–15]. 
Intracellular PRRs, including endosomal TLRs, are able to recognize nucleic acids to trigger signal 
cascades for the activation of NFκB and specific interferon regulatory factors (IRFs) leading to 
production of type I interferons (IFN-I) [15]. Among these “Toll-free” receptors, RLRs and cGAS play 
non-redundant roles in the recognition of cytosolic RNAs and DNAs respectively, and they govern 
intracellular IFN-I-mediated innate immune responses. The involvement of other cytosolic “Toll-free” 
sensing pathways in IFN-I-mediated innate immunity is controversial due to the lack of solid evidence 
of genetic studies [16]. Importantly, recent studies have shown that the IFN-I signaling pathway plays 
a dual role in chronic viral infections. At the early stage of infection, it has a potent antiviral activity; 
however, at late stages, a low level of prolonged IFN-I response facilitates the establishment and 
maintenance of persistent infection [17–22]. 
Except PAMPs, host damage-associated molecular patterns (DAMPs), such as self-nuclei acids, 
heat-shock proteins and HMGB1, are also recognized by PRRs [13]. Self-DNA can be accumulated in 
the cytoplasm in mammalian cells under stress and specific physiological conditions, including but not 
limited to apoptosis, DNA damage, and spontaneous aging/senescence. [14,23,24]. Reactive oxygen 
species (ROS) produced from damaged mitochondria are one of the major cause of DNA damage, 
especially those with double-strand breaks, apart from other servere effects such as cell-cycle arrest, 
senescence and cell death [25–29]. Accumulation of damaged DNA fragments is able to activate 
cGAS- or RIG-I-mediated aberrant production of persistent IFN-I and AIM2-mediated inflammatory 
responses, causing autoimmune diseases and cancerogenesis [16,30–35]. Persistent IFN-I production 
also triggers chronic immune activation, and ultimately results in immune exhaustion and senescence, 
in the setting of persistent infection by viruses such as HIV and HCV [19,36,37].  
Furthermore, there is substantial evidence showing that prolonged IFN-I signaling has important 
roles in regulating T cell responses in both direct and indirect manners, either promoting or inhibiting 
T cell activation, proliferation, differentiation and survival, and thus serves as a bridge that links innate 
and adaptive immune responses [19,20,21,38,39,40]. For example, CD4
+
 T cells derived from HIV
+
 
subjects display an anergic phenotype, and a recent report has shown that engagement of TLR7 in 
HIV-infected CD4
+
 T cells induces anergy/unresponsiveness, accounting for the impaired T cell 
function by chronic HIV infection [41].  
In essence, IFN-I production has to be finely tuned to ensure appropriate mounting of antiviral 
and anti-tumor immunity and to maintain cellular homeostasis. We outline the “Toll-free” pathways 
triggering IFN-I production in this review, highlighting cGAS, HIN200, and RLRs, and recent updates 
on their regulation by cellular and viral factors with enzymatic activities. 
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2. “Toll-free” Nucleic Acid-Sensing Innate Immune Pathways 
2.1. cGAS-STING cytosolic dsDNA-sensing pathway 
cGMP-AMP synthase (cGAS) synthesizes 2’3’-GMP-AMP (cGAMP) from ATP and GTP after 
binding to double-stranded DNA (dsDNA), and is the primary indispensable cytosolic sensor for both 
exogenous and endogenous dsDNA molecules, which, with the sizes of as short as 20 bp, are 
recognizable by high concentrations of cGAS or, with long sizes with bounded protein, recognizable 
by lower concentrations of cGAS [42]. In conjunct with ER-anchored IFN-inducible stimulator of 
interferon genes (STING, also called MITA, ERIS, MYPR) that functions as an adaptor to bind to 
cGAMP, cGAS-STING-mediated pathway plays a key role in innate immune responses against a large 
spectrum of DNA viruses (HSV1, vaccinia virus, adenovirus, KSHV, etc.), retroviruses (HIV1,   
HIV2, etc.) that produce pro-integrating DNA molecules, as well as bacteria (Mycobacteria, 
Legionella, Listeria, etc.) (Figure 1). In addition to viral infection, chemotherapeutic agents such as 
cisplatin, etoposide, and chitosan, induce oxidative DNA damage that promotes self-DNA leakage 
from the nucleus and mitochondrion, and therefore trigger cGAS-STING-mediated antitumor immune  
response (Figure 1) [28]. dsDNA molecules derived from retrotransposons such as short interspersed 
nuclear elements (SINEs) and Alu elements, can also function as ligands for cGAS. Approximately 
half of the mammalian genomes consist of retrotransposons [43]. 
 
Figure 1. cGAS-STING pathway senses cytosolic dsDNA. Cytosolic dsDNA derived 
from invading DNA viruses or retroviruses, or from self-genome under stress   
conditions (such as damaged mitochondrial DNA) binds to cGAS, leading the synthesis of 
cGAMP from ATP and GTP. cGAMP binds to STING dimers, resulting in STING 
phosphorylation and activation, further triggering downstream pathways for production of 
IFN-I and proinflammatory cytokines. 
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Binding of cGAMP to two STING protomers results in translocation of STING from the ER 
compartment to perinuclear autophagy-like vesicles, where TBK1 is autophosphorylated and recruited 
to STING, allowing STING to be phosphorylated at Ser366, which is in an evolutionary conserved 
serine cluster shared with MAVS, TRIF, and IRF3 so that they all are also activated through similar 
phosphorylation-dependent mechanism [44]. Phosphorylated STING further recruits IRF3, resulting 
in its phosphorylation and activation by TBK1. cGAMP can be transferred to adjacent non-infected 
cells to spread antiviral activity, by diffusion or by being packed into viral particles, and therefore 
cGAS-STING can mount unique regional immune response [28]. 
STING itself is a receptor for bacterial cyclic dinucleotides (CDN) and their binding activates 
IFN-I responses in mice but not in humans (Figure 1). Binding of CDN to STING dimers causes the 
relief of STING autoinhibition, which allows STING to be ubiquitinated with K27 chains by the 
ER-anchored E3 ligases AMFR, further leading to the recruitment of TBK1 for IRF3 activation [45].  
2.2. HIN200-mediated cytosolic dsDNA-sensing pathways  
Except cGAS, two other important receptors for cytosolic dsDNA, AIM2 and IFI16, belong to the 
HIN200/PYHIN family that includes 4 members in humans: AIM2 (PYHIN4), IFI16 (PYHIN2),  
IFIX (PYHIN1), and MNDA (PYHIN3). The members are hematopoietic interferon-inducible nuclear 
antigens with 200 amino acid repeats and an N-terminal PYHIN (Pyrin and HIN) domain (except p202 
in mice). Upon binding to DNA, both AIM2 and IFI16 trigger signal transduction to activate caspase 1 
inflammasome leading to cleavage of pro-IL1β and pro-IL18 into mature bioactive IL1β and IL18 via 
the CARD-containing adaptor ASC (CARD5) [46]. IFI16 preferentially recognizes longer naked  
DNA (>150 bp), and also triggers IFN-I responses via STING, in addition to its ability to induce 
caspase 1 inflammasome. AIM2 also triggers signal to caspase3-dependent apoptosis (Figure 2). Like 
cGAS, IFI16 and AIM2 bind to DNA independent of the DNA sequence [46].  
Infection of a DNA virus activates both cGAS and IFI16 in the cytoplasm. However, recent 
studies support that DNA viral genome initiates IFI16-mediated immune response in the nucleus, 
where episomal genomes of almost all DNA viruses residue and replicate [47]. At the same time, viral 
infection (such as herpesviruses) imposes cellular stress that triggers mitochondrial DNA damage and 
release to activate cGAS-STING pathway [48]. Of special interest, Epstein-Barr Virus (EBV) latent 
infection, which is associated with various malignancies, constitutively induces IFI16-ASC-caspase 1 
inflammasome that may represent a chronic inflammatory microenvironment for EBV-mediated 
oncogenesis [49].  
Single-stranded DNA (ssDNA) derived from retroviral genome reverse transcription or from 
DNA replication (named Y-form DNA) potently stimulates IFN-I responses depending on cGAS or 
IFI16; whereas the RNA:DNA intermediate derived from reverse transcription prior to host genomic 
integration is detected by TLR9 and cGAS [50].  
The other two HIN200 family members, IFIX and MNDA, are less studied but existing evidence 
has shown that they are involved in regulation of IFN signaling in cancers. IFIX promotes 
ubiquitination-mediated degradation of MDM2, leading to p53 stabilization, and stimulates maspin 
expression by promoting ubiquitination-mediated degradation of HDAC1, leading to impaired 
invasion activity of cancer cells. 
147 
AIMS Allergy and Immunology                                  Volume 1, Issue 3, 143-163. 
 
Figure 2. HIN200-mediated cytosolic dsDNA-sensing pathways. The dsDNA sensors 
AIM2 and IFI16 in the HIN200 family recognize long viral genome DNA in the cytoplasm, 
triggering caspase 3-mediated apoptosis and caspase 1-mediated inflammation. 
Recognition of dsDNA by IFI16 also triggers STING-mediated IRF3/7 activation and 
IFN-I production. While AIM2 activates caspases to trigger apoptosis and inflammation, 
mouse P202 inhibits AIM2-mediated pathways. 
2.3. RLR cytosolic RNA-sensing pathways 
RLRs include RIG-I (DDX58), MDA5 (IFIH1), and LGP2, all of which contain a central DEAD 
box helicase/ATPase domain and a C-terminal regulatory domain (CTD); the latter (CTD) is essential 
for RNA binding. RIG-I and MDA5 each contains 2 CARD domains, and both signal through the 
mitochondrial CARD-containing antiviral signaling adaptor MAVS (also called VISA, IPS1, or 
CARDIF) that is located on mitochondrial membrane. RIG-I recognizes dsRNA synthesized from 
AT-rich dsDNA derived from DNA viruses (EBV, HSV1) and bacteria [5], and recognizes 5’-ppp 
ssRNA derived from the RNA viruses NDV, VSV, Sendai virus, influenza A virus and JEV; while 
MDA5 recognizes >300 bp long dsRNA such as poly (I:C) and RNA from EMCV and   
paramyxovirus (Figure 3) [51]. Solid evidence have shown that STING is also involved in RIG-I 
signaling, and interacts with MAVS in a complex that is stabilized in response to RNA virus infection, 
potentiating RIG-I-mediated antiviral responses (Figure 3) [51]. In the absence of ligand challenges, 
RIG-I and MDA5 are inactive due to phosphorylation at specific Thr and Ser residues (Ser8 and 
Thr170 of RIG-I, and Ser88 of MDA5), which is mediated by casein kinase II (CKII) and protein 
kinase C (PKC)-α/β respectively for RIG-I and by RIOK3 for MDA5. Activation of RIG-I and MDA5 
requires their dephosphorylation by PP1α/γ, ubiquitination, and ATP-dependent conformational 
changes leading to their multimerization upon binding to RNA. The other member, LGP2, can 
recognize RNA but lacks CARD domains, and results from knockout mice have shown that LGP2 is in 
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fact a positive regulator of RIG-I/MDA5 signaling [52]. Different from TLRs that are restrictedly 
expressed in immune cells, epithelial cells and synovial fibroblasts, RLRs are expressed in most cell 
types. 
 
Figure 3. RLR-mediated RNA sensing pathways. RIG-I and MDA5 recognize different 
patterns of cytosolic RNA fragments derived from viruses, bacteria, or the host cell. 
STING interacts with RIG-I and MAVS in a complex that is stabilized upon RNA virus 
infection, facilitating the antiviral response. In addition, AT-rich dsDNA derived from 
bacteria or DNA viruses can be transcribed by RNA polymerase III into 5’-ppp dsRNA, 
which activates RIG-I-MAVS-TBK1-IRF3 pathway for IFN-I production. 
2.4. Other “Toll-free” cytosolic innate sensing pathways for IFN-I production  
An increasing pool of individual cytosolic DNA and RNA sensors have been identified. Almost 
all these sensors trigger IFN-I production [13], except OASs that recognize dsRNA leading to RNA 
degradation by RNase L, and Sox2 that recognizes dsDNA triggering NFκB/AP1-mediated 
inflammation via activating the kinase complex TAK1-TAB2 (Figure 4) [8]. The adaptor STING 
converges different DNA sensing pathways for IRF3 activation leading to IFN-I production [53].  
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Figure 4. Cytosolic nucleic acid sensors triggering innate immune responses. An 
increasing pool of cytosolic “Toll-free” nucleic acid sensors have been identified in 
addition to cGAS-STING, RLRs, and the HIN200 family. They usually use STING to 
transmit their signal for the production of IFN-I via activating IRF3.  
3. Evasion of “Toll-free” Innate Signaling Pathways 
Innate sensing pathways are circumvented by numerous viral and cellular negative     
regulators (Figures 5 and 6). For example, Kaposi’s sarcoma-associated herpesvirus (KSHV)-encoded 
ORF52 and its homologs in other gammaherpesviruses (EBV, MHV68 and Rhesus monkey 
Rhadinovirus) inhibit cGAS activity to facilitate virus progeny [54,55]; KSHV-encoded vIRF1 
negatively regulates STING-TBK1 interaction [56], and vIRF4 inhibits IRF7 transcriptional   
activity [57]. Some dsDNA and ssDNA viruses express proteins, including HPV E7 and human 
adenovirus E1A oncoproteins, with the Leu-x-Cys-x-Glu (LxCxE) motif that is known to block the Rb 
tumor suppressor [58]. The LxCxE motif mediates their interaction with STING to block IFN-I 
immune responses. Since these proteins are frequently used to immortalize cell lines [59], 
cGAS-STING pathway in these immortalized cell lines is compromised [50]. 
Nevertheless, those regulators with enzyme activities, such as DNA and RNA editing enzymes, 
kinases and phosphatases, ubiquitin E3 ligases and deubiquitinases, and histone modification enzymes, 
are especially interesting in that these regulators are potentially targeted with enzyme inhibitors for 
clinical interventions. In regard to evasion of HIV infection, these interesting enzymes include the 
RNA editing enzyme APOBEC3G, the ubiquitin E3 ligases TRIM5α and TRIM22, the exonucleases 
TREX1 and SAMHD1, and the GTPase Mx2, and they are all inducible by IFN-I. Tetherin (BST2), 
another IFN-inducible host restriction factor with broad antiviral activity (including HIV1), directly 
tethers virions for internalization, leading to endocytosis and subsequently degradation [60,61]. 
Apoptotic caspases have also been found to negatively regulate cGAS-STING pathway, although the 
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precise mechanism remains unclear [24,62]. Of note, many PRRs themselves have enzymatic activity, 
including RLRs, cGAS, and DDXs, and some of their family members negatively regulate PRR 
signaling pathways; for example, DDX46 negatively regulates IFN-I responses by retaining antiviral 
mRNAs of TRAF3, TRAF6, and MAVS in the nucleus through eliminating their m6A modification [63]. 
 
Figure 5. Regulation of cGAS and STING by cellular and viral factors. Phosphorylation 
and ubiquitination are two major posttranslational modifications that regulate cGAS and 
STING protein stability and activity. Many viral factors, with or without enzyme activity, 
may also regulate their activities through other mechanisms, including direct interaction 
and employment of cellular factors as mediators. 
Apart from protein regulators, miRNAs represent another interesting category of immune 
inhibitors with clinical potentials [64,65,66]. For example, miR-27 targets STING gene 3’UTR and 
represses its expression, resulting in impaired CCL22-mediated recruitment of Tregs in human 
papillomavirus (HPV)-positive tongue squamous cell carcinoma (TSCC) [67]. STING, in addition to 
MAVS and IRF3, is also targeted for downregulation by miR-576-3p [68]. Hypoxia induces 
Tet1-dependent expression of miR-25/93 that targets NCOA3, a lysine acetyltransferase that 
epigenetically induces cGAS expression in cooperation with AP1, resulting in suppression of cGAS 
expression in hypoxic breast cancers [69].  
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Figure 6. Regulation of RLR signaling components. The receptors RIG-I and MDA5, the 
adaptor MAVS, and the downstream IRF3/7 are shown as examples in the RLR signaling 
pathways for their regulation by phosphorylation and ubiquitination at the 
posttranslational level. Many viral factors may also regulate their activities through other 
mechanisms. 
3.1. Evasion of nucleic acid sensing pathways by AGS exonucleases 
The family of AGS exonucleases, including AGS1-5, are RNases except AGS1 (TREX1) that 
functions as a DNase. However, our recent in vitro biochemical evidence have shown that AGS1 can in 
fact also act as an RNase, which specifically degrades ssRNA [70]. Attraction is especially focused on 
AGS1 and AGS5 (SAMHD1) because of their roles in HIV1 infection. TREX1 is responsible for the 
degradation of self-DNA in the cytosol. In the absence of TREX1, viral infections including HIV1 
infection cause accumulation of cytoplasmic DNA, which activates the cGAS-STING pathway 
leading to IFN-I production and eventually viral replication is inhibited. Deficiency of TREX1 also 
causes Aicardi-Goutieres syndrome, a childhood inflammatory disorder characterized by high 
endogenous levels of IFN-I resulting from activation of DNA sensors by excess endogenous DNA. 
3.2. Evasion of RNA sensing pathways by RNA editing enzymes 
The RNA editing enzymes in humans consist of the adenosine deaminases that act on       
RNA (ADARs, A-to-I) family and the cytidine deaminases (AID/APOBECs, C-to-U) family. 
The double-stranded RNA (dsRNA) A-to-I adenosine deaminase acting on RNAs (ADARs) 
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include ADAR1 (IFI4), ADAR2, and ADAR3. ADAR1 has two forms; the longer form p150 is 
IFN-inducible but the shorter form p110 is constitutively expressed, ADAR2 is constitutively 
expressed, and ADAR3 has no enzyme activity [71]. Bioinformatics analysis has indicated that only 
limited sites in human transcriptome are potentially edited by ADARs; however, it is estimated 
approximately 20% of the human miRNA precursors are subject to ADAR editing, and in 
IFN-mediated antiviral responses, specific editable sites are increased [71]. Also, retrotransposons, 
which represent nearly half of the mammalian genomes, undergo extensive A-to-I editing [72]. 
ADAR1 also competes with RIG-I and MDA5 for dsRNA binding independently of its RNA editing 
activity and therefore suppresses IFN response upon RNA virus infection [73], and also negatively 
regulates OAS1- and PKR-mediated immune responses. Due to its ability to act on both cellular and 
viral dsRNAs, ADAR1 has broad roles in repressing antiviral immunity and preventing autoimmune 
diseases [74]. However, for some other viruses, including HCV and influenza virus, A-to-I editing of 
viral RNAs promotes antiviral activity [74]. 
Furthermore, ADARs have been shown to regulate DNA virus latent infection such as the 
oncogenic KSHV and EBV that encode ADAR-targeted RNA transcripts [74]. Site-specific A-to-I 
RNA editing of KSHV oncogenic K15 transcript (encodes miR-K10 and kaposin A) abrogates its 
transforming activity and promotes KSHV replication [75]. The EBV pre-miR-BART6 transcript 
undergo A-to-I editing that negatively regulates miR-BART6 biological functions [76]. A-to-I editing 
of viral transcripts at multiple sites may alter ORFs and results in aberrant expression of viral proteins. 
The AID/APOBEC C-to-U family, including eleven members, can selectively act on either RNA 
or ssDNA [77]. Among these members, AID and APOBEC3 (APOBEC3A-H), are of great interest 
due to their antiviral activity against HBV, HCV, HIV, HTLV1, HPV, and herpesvirus infection [77]. 
The ssDNA deaminase AID, which is primarily expressed in germinal center (GC) B cells and is the 
only enzyme known to induce oncogenic mutations in the human genome, is induced upon infection 
with HCV or Helicobacter pylori, and is also induced by EBV LMP1 and HTLV1 Tax via NFκB in 
their latency. APOBEC3 deaminases are only expressed in mammalians and inhibit retroviral infection 
by deaminating their DNA intermediates. For example, APOBEC3G defends viral infectivity    
factor 1 (VIF1)-deficient HIV infection; however, VIF1 causes APOBEC3G ubiquitination-dependent 
degradation. Similar to AID, APOBEC editing causes endogenous “off-target” DNA damage and 
genomic instability favoring cancer development, for example, in the setting of oncogenic HPV 
infection [77].  
3.3. Evasion of type I IFN responses by protein kinases and phosphatases 
Protein kinases usually activate PRR signaling by phosphorylating their components on specific 
sites. For example, the adaptors TRIF, MAVS and STING are phosphorylated at a serine site in a 
conserved motif pLxIS by TBK1 and IKKε for the recruitment of IRF3 [44], and phosphorylation of 
IRF3 and IRF7 by IKKs or IRAK1 is prerequisite for their activation leading to IFN-I production. 
STING Ser366 phosphorylation by TBK1 is believed to be required for its activation [44], although 
another report showed that phosphorylation of this site by autophagy-related kinases ULK1 (ATG1) 
and ULK2 diminishes STING activity [78]. However, site-specific phosphorylation of some 
components may cause their inactivation. For example, phosphorylation of human cGAS S305 (S291 
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in mouse) by Akt potently inhibits cGAS enzymatic activity [79]. Phosphorylation of IRF3 Ser97 
inhibits its activity but the phosphatase pTEN releases this inhibition to promote IRF3-mediated IFN-I 
antiviral responses [80]. Phosphorylation of RIG-I by IKKε or PKCα/β negatively regulates its 
activity.  
Recently, the roles of protein phosphatases in antiviral immune responses have emerged. PP1 and 
PP2A are positive regulators of Tat-dependent HIV1 transcription, and the 
35
QVCF
38
 motif of Tat 
directly interacts with PP1 [81]. PP1 also dephosphorylates the RNA sensors, MDA5 and RIG-I, and 
positively regulates their activity for IFN-I production in response to RNA virus infection [82,83]. 
Additionally, PP1 interacts with TRAF6, and promotes TRAF6-dependent innate immune responses [84].  
In contrast, PP1 dephosphorylates Ebola virus VP30 and inhibits its transcription [85]. The 
measles virus V and the HBV X proteins can antagonize PP1 activity to facilitate their      
replication [83,86]. PP1 negatively regulates IRF3-mediated IFN-I production by inhibiting its 
phosphorylation at serines 396 and 385 [87], and together with GADD34, negatively regulates 
TLR-mediated immune response by inhibiting TAK1 serine 412 phosphorylation [88,89]. PP2A also 
deactivates IRF3 in cooperation with FBXO17 [90], and inhibits IFN-I signaling by inhibiting STAT1 
phosphorylation and therefore contributes to HCV chronic infection [91]. More recently, we have 
identified PP1 as the first phosphatase that inactivates IRF7 by targeting its key phosphorylation sites 
and abrogates IRF7-mediated IFN-I responses [92]. Further verification of this important finding in 
mouse models in vivo is necessary.  
3.4. Evasion of “Toll-free” innate pathways by ubiquitinases and deubiquitinases 
Besides phosphorylation/dephosphorylation, ubiquitination/deubiquitination represent another 
major epigenetic modification that is committed to fine regulation of myriad cellular functions. It 
seems all components in each PRR signaling pathway, including the receptor, the adaptor, TRAFs, and 
downstream IRFs, are regulated by ubiquitination (Figures 5 and 6) [93,94,95]. The involved cellular 
E3 ligases mainly include the TRAF, TRIM, and RNF families, and the cellular deubiquitinases mainly 
include the OTU and USP families [96,97]. For example, the deubiquitinases Gumby (OTULIN), 
OTUD7b, and TNFAIP3 (A20) in the OUT family were shown to negatively regulate NFκB activation 
through different mechanisms in different biological contexts [98–104].  
The ER-anchored RNF185 triggers K27-linked ubiquitination of cGAS promoting its   
activation [105]; AMFR-mediated K27-linked ubiquitination and TRIM32, TRM56, or 
MUL1-mediated K63-linked ubiquitination of STING are required for its activation [45,106,107,108], 
but HTLV1 Tax and HBV polymerase negatively regulate STING K63-linked ubiquitination, and the 
cellular E3 ligases RNF5 and TRIM30α triggers STING K48-linked ubiquitination and degradation to 
alleviate cytosolic DNA sensing pathways [109–112]. RNF26 protects STING from RNF5-mediated 
degradation by targeting the same site (K150) for K11-linked ubiquitination, whereas promotes 
autophagy-mediated degradation of IRF3 [113]. USP21, a deubiquitinase, is recruited to STING after 
HSV1-stimulated phosphorylation via p38 and negatively regulates STING activity by hydrolyzing 
K27- and K63-linked ubiquitin chains of STING [114]. 
TRIM65 triggers K63-linked ubiquitination of MDA5 [115], and TRIM31 triggers K63-linked 
ubiquitination of downstream adaptor MAVS [116], both promoting RIG-I signaling pathway; 
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whereas the membrane-anchored TRIM13 and TRIM59 negatively regulate MDA5-mediated IFN-I 
responses but promotes RIG-I activity through unclear mechanism that may involve additional 
cofactors [117]. TRIM4, TRIM25/RNF147, and Reul/RNF135/RIPLET E3 ligases promotes RIG-I 
K63-linked ubiquitination and activation [118–122]. In contrast, RNF122 and RNF125 target RIG-I 
for ubiquitination-mediated degradation [123,124].  
TRIM21 targets IRF3 and DDX41, and TRIM26 and SENP2 target IRF3, for degradation, and 
TRIM21 also negatively regulates FADD-mediated antiviral immunity. TRIM35 targets IRF7 for 
degradation. We have shown that TRAF6 E3 ligase promotes IRF7 K63-linked ubiquitination that is 
required for EBV LMP1 activation of IRF7 [125]; however, A20, a member with both E3 ligase and 
deubiquitinase activities in the OTU family, inhibits LMP1-stimulated IRF7 activity by acting as a 
deubiquitinase [126].  
In recent years, LUBAC-mediated linear polyubiquitination is coming into focus due to its 
emerging role in activation of NFκB in response to diverse signaling stimuli [127–132], including 
apoptotic and immune stimuli such as TNFα [133,134], IL1β [135], genotoxic stress [136], CD40 [137], 
Toll-like receptors (TLRs) [138], NOD2 [98], and NLRP3 [139]. LUBAC is a ternary ubiquitin ligase 
complex composed of HOIP (RNF31), HOIL1L (RNF54), and SHARPIN, and is constitutively 
formed under normal physiological conditions [133,134,140]. RNF31 is likely the central component 
of this complex [141]. LUBAC components are abundantly expressed in thymus and spleen, implying 
its potential role in lymphocytes [130]. Recent reports clearly show that LUBAC specifically activates 
the canonical NFκB pathway, but not the JNK pathway, by conjugating linear polyubiquitin chains 
onto NEMO and RIP1 [130,142] . However, LUBAC negatively regulates RIG-I-mediated innate 
immune responses by targeting RIG-I, TRIM25 and IRF3 for degradation [143,144], and by disrupting 
the TRAF3-MAVS complex [145]. We have recently shown that LUBAC-mediated linear 
ubiquitination is required for LMP1 activation of NFκB, but inhibits LMP1-stimulated IRF7   
activity [146].  
Compared with host cellular factors, virus-encoded factors are of greater interest in that they are 
virus-specific and easier to manipulate without affecting bypass cellular functions. Herpesvirus-encoded 
E3 ligases have been found to play crucial roles in evading innate immune responses for facilitating their 
infection and establishment of latent infection. For example, HSV1 ICP0 and HCMV pUL83 ubiquitin 
E3 ligases target IFI16 for proteasome-dependent degradation [147,148]. KSHV IE lytic transactivator 
RTA/ORF50 functions as a ubiquitin E3 ligase that targets IRF7 for degradation [149]. Herpesviruses 
also encode deubiquitinases, many of which have also been shown to evade innate immune responses. 
For example, EBV-encoded BPLF1 functions as a deubiquitinase that suppresses NFκB activation 
downstream of TLR signaling [150].  
Ubiquitination-like modifications, especially sumoylation, have been shown to exert similar 
functions to ubiquitination in antiviral regulation. For example, TRIM38 stabilizes cGAS and STING 
by promoting their sumoylation [151], and TRIM28 is a SUMO E3 ligase that promotes IRF7 
sumoylation and negatively regulates its activity [152]. These intriguing findings have advanced our 
current understanding of the novel functions of ubiquitination-like posttranslational modifications in 
signal transduction pathways [153,154]. 
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4. Closing Remarks 
The increasing pool of cytosolic nucleic acid receptors have greatly advanced the study of 
IFN-I-mediated innate immune mechanisms, and may also shed light on type III IFNs-mediated 
responses that involve similar induction mechanisms to IFN-I. It is plausible that better understanding 
of innate immune pathways will benefit clinical applications for both antiviral infections and 
inflammation-related diseases including cancers. Recent research brings cGAS-STING pathway to the 
focus for potential treatments of cancers in that this pathway plays crucial roles in antitumor immunity 
and is aberrantly regulated in many cancers [28]. Future efforts may concentrate on the identification 
of viral and cellular regulators of these signaling pathways so as to design appropriate strategies such 
as cancer vaccines to evoke or interfere with their functions in different related disease settings, 
including cancers and autoimmune disorders. 
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